Anti-inflammatory Patents (Class 514/12.2)
-
Patent number: 8288350Abstract: Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.Type: GrantFiled: May 19, 2011Date of Patent: October 16, 2012Assignee: Nour Heart, Inc.Inventors: Salwa A. Elgebaly, Elliott Schiffmann
-
Publication number: 20120251562Abstract: The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.Type: ApplicationFiled: November 23, 2010Publication date: October 4, 2012Inventor: Philippe Pierre
-
Publication number: 20120231994Abstract: The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases.Type: ApplicationFiled: June 2, 2010Publication date: September 13, 2012Applicant: NIKAN PHARMACEUTICALS, LLCInventor: John D. Benson
-
Publication number: 20120230955Abstract: The present invention is directed to a particular arabinoxylan (“AX”) preparation and the finding that this preparation has a beneficial effect on the organization of the intestinal microbial community in the lumen and in particular at the site of the gut mucosa, where it modulates the barrier function of the intestinal surface, primarily by modulating the mucosa-associated microbial community towards a relative increase of health beneficial bacteria, such as bifidobacteria and lactobacilli. It is accordingly a first aspect of the present invention to provide said arabinoxylan preparation characterized in comprising isolated water-soluble arabinoxylans and the use thereof to improve functioning (e.g. barrier function) of the intestinal epithelium.Type: ApplicationFiled: August 18, 2009Publication date: September 13, 2012Applicant: BioActor bvbaInventors: Peter Frank Ekhart, Hans Van De Saag, Sam Possemiers, Pieter Van Den Abbeele, Tom Van De Wiele, Audrey Martine Neyrinck, Nathalie Maria Nelly Delzenne, Patrice D. Cani
-
Publication number: 20120225057Abstract: Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.Type: ApplicationFiled: September 8, 2011Publication date: September 6, 2012Applicant: DECIPHERA PHARMACEUTICALS, LLCInventors: Daniel L. Flynn, Michael D. Kaufman
-
Publication number: 20120220526Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: ApplicationFiled: May 9, 2012Publication date: August 30, 2012Applicant: Synergy Pharmaceuticals, Inc.Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Publication number: 20120213790Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 20, 2012Publication date: August 23, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 8242074Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.Type: GrantFiled: September 14, 2009Date of Patent: August 14, 2012Assignee: XBiotech, Inc.Inventor: John Simard
-
Publication number: 20120202735Abstract: Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.Type: ApplicationFiled: March 15, 2012Publication date: August 9, 2012Applicant: Carrus Capital CorporationInventors: Timothy J. Krieger, Patricia J. McNicol
-
Publication number: 20120195932Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.Type: ApplicationFiled: January 25, 2010Publication date: August 2, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
-
Publication number: 20120190611Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.Type: ApplicationFiled: July 13, 2011Publication date: July 26, 2012Inventors: Liora Braiman-Wiksman, Tamar Tennenbaum, Yuvai Sagiv, Marina Gartsbein, Ephraim Brener, Moshe Ben-Hamo, Liat Hammer
-
Publication number: 20120189619Abstract: Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro®-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation.Type: ApplicationFiled: October 24, 2011Publication date: July 26, 2012Applicant: WARSAW ORTHOPEDIC, INC.Inventor: Francois Binette
-
Patent number: 8222211Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias. In addition PIF peptides enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators, therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.Type: GrantFiled: October 22, 2004Date of Patent: July 17, 2012Assignee: BioIncept, LLCInventor: Eytan R. Barnea
-
Publication number: 20120177715Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: ApplicationFiled: September 21, 2010Publication date: July 12, 2012Applicant: XIMMUNE ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Björn Ulrik Walse
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Compositions and Methods for Treatment of Thrombosis and for Prolonging Survival of Stored Platelets
Publication number: 20120165258Abstract: Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets.Type: ApplicationFiled: June 24, 2011Publication date: June 28, 2012Applicant: VASCULOGICS, INC.Inventor: Gray D. Shaw -
Patent number: 8207292Abstract: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.Type: GrantFiled: February 12, 2008Date of Patent: June 26, 2012Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
-
Patent number: 8202835Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: GrantFiled: July 15, 2008Date of Patent: June 19, 2012Inventor: Yitzchak Hillman
-
Patent number: 8188053Abstract: The present invention relates, inter alia, to a method of ameliorating an inflammatory skin condition. Thus, the present invention provides a peptide that includes the amino acid sequence KMIKP (SEQ ID NO: 20), wherein the peptide includes no more than 70 amino acids and wherein the peptide is capable of inhibiting allergen induced Langerhans cell migration, and wherein the peptide is not that depicted in SEQ ID NO. 19. The present invention also relates to the use of a peptide that includes the amino acid sequence KMIKP (SEQ ID NO: 20), wherein the peptide includes no more than 100 amino acids, and wherein the peptide is capable of inhibiting allergen induced Langerhans cell migration, in the manufacture of a topical medicament for the treatment of an inflammatory skin condition.Type: GrantFiled: December 4, 2006Date of Patent: May 29, 2012Assignee: The University of ManchesterInventors: Marie Cumberbatch, Rebecca Jane Dearman, Ian Kimber, Russell Colin Viner
-
Patent number: 8188058Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.Type: GrantFiled: April 17, 2008Date of Patent: May 29, 2012Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: David J. Hackam, Steven C. Gribar
-
Patent number: 8173595Abstract: The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIb? fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3.Type: GrantFiled: April 27, 2005Date of Patent: May 8, 2012Assignee: The Board of Trustees of the University of IllinoisInventors: Kesheng Dai, Xiaoping Du
-
Patent number: 8168176Abstract: Methods of treating endotoxin-mediated disorders are provided.Type: GrantFiled: November 12, 2007Date of Patent: May 1, 2012Assignee: The Board of Trustees of the University of IllinoisInventors: Kurt Bachmaier, Asrar B. Malik
-
Patent number: 8163696Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.Type: GrantFiled: December 21, 2009Date of Patent: April 24, 2012Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Yvette Miata Petersen
-
Publication number: 20120094911Abstract: The present invention provides peptides capable of sustaining antagonist activity against substance P for long periods of time. A peptide selected from (a) to (d) can sustain antagonist activity against substance P, analgesic activity, and anti-inflammation activity for a long period of time: (a)?Ala-Tyr-Gln-Leu-Glu-His-Thr-DTrp-Gln-Gly-Leu- Leu-NH2; (b) a peptide consisting of a partial sequence of (a), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-DTrp-Gln-Gly-Leu-Leu-NH2; (c) Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-DTrp-Leu-Leu-NH2; and (d) a peptide consisting of a partial sequence of (e), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-Phe-Gln-DTrp-Leu-Leu-NH2.Type: ApplicationFiled: May 31, 2010Publication date: April 19, 2012Applicant: UNIVERSITY OF MIYAZAKIInventors: Toshikazu Nishimori, Rumi Naono
-
Patent number: 8153583Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.Type: GrantFiled: November 30, 2005Date of Patent: April 10, 2012Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
-
Publication number: 20120077747Abstract: A peptide-comprising extract derived from fish is described. Also disclosed is a process for obtaining a peptide-comprising extract derived from fish, as well as an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for example to prevent and/or treat an inflammatory and/or immune disease-related discomfort in a subject, are also described.Type: ApplicationFiled: October 23, 2009Publication date: March 29, 2012Applicant: Innovactiv Inc.Inventors: Raphael Anguenot, Martin Beaulieu, Jocelyn Bérubé, Sandrine Briate
-
Publication number: 20120077731Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: April 12, 2010Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Patent number: 8138141Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: July 1, 2009Date of Patent: March 20, 2012Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Publication number: 20120052077Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.Type: ApplicationFiled: January 13, 2010Publication date: March 1, 2012Inventors: Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
-
Publication number: 20120046218Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.Type: ApplicationFiled: January 29, 2010Publication date: February 23, 2012Applicant: PROTAFFIN BIOTECHNOLOGIE AGInventor: Andreas Kungl
-
Publication number: 20120039849Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: ApplicationFiled: August 17, 2011Publication date: February 16, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Alex Aronov, Upul Keerthi Bandarage, Kevin Michael Cottrell, Robert J. Davies, Elaine B. Krueger, Mark Willem Ledeboer, Brian Ledford, Arnaud Le Tiran, David Messersmith, Tiansheng Wang, Jinwang Xu, Yusheng Liao
-
Publication number: 20120039888Abstract: The present invention relates to compositions and methods for treating inflammation-associated tissue damage, and particularly transfusion-associated, disorders, by inhibiting or reducing E-selectin mediated signal transduction pathways, such as E-selectin mediated activation of ?M?2.Type: ApplicationFiled: May 10, 2011Publication date: February 16, 2012Inventors: Paul Frenette, Andrés Hidalgo
-
Patent number: 8114394Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.Type: GrantFiled: September 22, 2010Date of Patent: February 14, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Catherine Vicary, Scott Mellis
-
Patent number: 8114831Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: GrantFiled: April 20, 2010Date of Patent: February 14, 2012Assignee: Synergy Pharmaceuticals Inc.Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20120034164Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated CAR peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.Type: ApplicationFiled: September 1, 2011Publication date: February 9, 2012Inventors: Erkki Ruoslahti, Tero Järvinen, Masanobu Komatsu
-
Patent number: 8106018Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: GrantFiled: June 28, 2010Date of Patent: January 31, 2012Assignee: NovImmune S.A.Inventor: Greg Elson
-
Publication number: 20120020991Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.Type: ApplicationFiled: October 7, 2011Publication date: January 26, 2012Applicant: BioZyme, Inc.Inventors: Marcia Moss, Pei Zhou
-
Publication number: 20120014904Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.Type: ApplicationFiled: November 24, 2010Publication date: January 19, 2012Inventors: Ayelet DAVID, Gonen Ashkenszy, Yosi Shamay
-
Patent number: 8097589Abstract: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucus release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.Type: GrantFiled: November 19, 2007Date of Patent: January 17, 2012Assignee: Mowyeal Lending, LLCInventors: John C. Houck, Mary MacDonald, legal representative, James Clagett
-
Publication number: 20120004175Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.Type: ApplicationFiled: March 28, 2008Publication date: January 5, 2012Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Zhiquan Zhang, Basil Rigas
-
Publication number: 20110312879Abstract: Template-fixed peptidomimetics formula (Ia) formula (Ib) wherein Z is a template-fixed chain of 14 ?-amino and/or ?-hydroxy acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Pro, Gly, a glycolic acid residue or of certain types which, as the remaining symbols in the above formulae, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties and can be used for preventing HIV infections in non-infected individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immuno suppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair.Type: ApplicationFiled: November 26, 2008Publication date: December 22, 2011Applicant: POLYPHOR AGInventors: Frank Gombert, Daniel Obrecht, Alexander Lederer, Barbara Romagnoli
-
Patent number: 8080518Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: GrantFiled: November 26, 2008Date of Patent: December 20, 2011Assignees: Arbor Vita Corporation, Nono Inc.Inventors: Michael Tymianski, Jonathan David Garman
-
Publication number: 20110305634Abstract: The present invention provides compositions and methods for treating disorders associated with epithelial tissues.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Publication number: 20110300245Abstract: The invention is a new unique, palatable, topical, anti-inflammatory and analgesic designed around a specific set of painful conditions, with specifically designated applications, using a different methodology and formulation, with no NSAIDS, steroids or salicylites, than the prior art for this specific set of painful conditions. Thus creating an improved dissimilar system, preventing the prior arts required invasive, costly and inefficient medical procedures, and with a unique lack of negative effects when compared with the prior art. Thereby, facilitating an anti-inflammatory analgesic effect to areas correlating or relating to the trigeminal nervous system, both intraoral and extraoral.Type: ApplicationFiled: June 3, 2010Publication date: December 8, 2011Inventor: Wendy Lou Marshall
-
Publication number: 20110301087Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor for corticotrophin releasing hormone (or factor) receptor 1, also known as the CRF1, CRHR1, CRFR1, CRHR, CRF-R. The CRF1 receptor compounds are derived from the intracellular loops and domains of CRF1 receptor. The invention also relates to the use of these CRF1 receptor compounds and pharmaceutical compositions comprising the CRF1 receptor compounds in the treatment of diseases and conditions associated with CRF1 receptor modulation, such as inflammatory bowel disease (peripherally acting), irritable bowel syndrome (IBS), stress response (colonic motor activity), anxiety, sleep disorder, addictive behavior, acute and chronic neurodegeneration, preterm labor and pain.Type: ApplicationFiled: November 4, 2009Publication date: December 8, 2011Inventors: Edward McBride, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20110300148Abstract: The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role.Type: ApplicationFiled: November 17, 2009Publication date: December 8, 2011Inventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 8066981Abstract: The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating inflammation. In some embodiments, the invention relates to antagonists of TLR3, to amino acid sequences that act as dominant negative molecules, and to nucleic acid sequences that encode said amino acid sequences. In additional embodiments, the invention relates to the manipulation of biological materials to evaluate TLR3 activity.Type: GrantFiled: November 14, 2007Date of Patent: November 29, 2011Assignee: The Texas A & M University SystemInventors: Cheng C. Kao, Ranjith Kumar Tharachaparamba
-
Patent number: 8067371Abstract: This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating inflammatory disorders such as rheumatoid arthritis. The instant invention is based on the blockade of RAGE G82S function.Type: GrantFiled: May 7, 2004Date of Patent: November 29, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: Ann Marie Schmidt, David M. Stern
-
Patent number: 8063182Abstract: The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.Type: GrantFiled: May 19, 1995Date of Patent: November 22, 2011Assignee: Hoffman-LaRoche Inc.Inventors: Manfred Brockhaus, Reiner Gentz, Dembic Zlatko, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
-
Patent number: 8058241Abstract: A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-?B and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal transduction in TAB2 is useful as an anti-inflammatory drug.Type: GrantFiled: December 4, 2006Date of Patent: November 15, 2011Inventor: Kunihiro Matsumoto